Reshaping the HIV treatment and prevention landscape

Translating label expansion into higher market share US: Most prescribed PARPI for new patients in 1LM 80% EU5: Most prescribed PARPI across all lines for new patients 50% gsk 45% 70% 40% 60% 56% 35% 35% 50% 30% 40% 25% 20% 30% 15% 20% 10% 10% 5% 0% 0% Dec Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec Jan Feb Mar '19 '20 '20 '20 '20 '20 '20 '20 '20 '20 '20 '20 '20 '21 '21 '21 Oct-20 Nov-20 Dec-20 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Zejula Zejula Competitor A Competitor B Competitor A Competitor B bevacizumab Source: IQVIA APLD Source: Evidera MQT April ‘21 34

View entire presentation